纳米受体击退突变 p53

IF 72.5 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2024-02-06 DOI:10.1038/s41568-024-00675-w

Gabrielle Brewer

引用次数: 0

摘要

突变的功能增益 p53 常见于人类癌症。Huang、Cao、Qian 等人开发并验证了多功能仿生纳米受体作为癌症疗法的用途，这种受体能与突变 p53 结合并促进其降解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Nanoreceptors take down mutant p53

查看原文本刊更多论文

Nanoreceptors take down mutant p53

Mutant gain-of-function p53 is commonly found in human cancers. Huang, Cao, Qian et al. developed and validated the use of multifunctional biomimetic nanoreceptors that bind to and promote the degradation of mutant p53 as a cancer therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.